SCHEMBL7690658

SCHEMBL7690658

Cc1ccc2[nH]c(COc3ccc(Cl)cc3)nc2c1C

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
NPC1 O15118 5/20 0.56
POLB P06746 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
HRH4 Q9H3N8 2/20 0.41
TP53 P04637 2/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 2/20 0.40
CBFB Q13951 1/20 0.40
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39
ALOX15 P16050 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
DGAT2 Q96PD7 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7689804 0.84 RAB9A (0.63) RAB9ASMN1; SMN2NPC1POLBTDP1
SCHEMBL8555194 0.81 SMN1; SMN2 (0.47) RAB9ASMN1; SMN2NPC1POLBTDP1
SCHEMBL8553989 0.81 RAB9A (0.47) RAB9ASMN1; SMN2NPC1POLBTDP1
SCHEMBL8557031 0.80 RAB9A (0.46) RAB9ASMN1; SMN2NPC1POLBTDP1
SCHEMBL8554128 0.80 RAB9A (0.46) RAB9ASMN1; SMN2NPC1POLBTDP1
SCHEMBL7690656 0.78 RAB9A (0.56) RAB9ASMN1; SMN2NPC1POLBTDP1
SCHEMBL8551098 0.78 RAB9A (0.45) RAB9ASMN1; SMN2NPC1POLBTDP1
SCHEMBL7961264 0.78 RAB9A (0.51) RAB9ASMN1; SMN2NPC1POLBTDP1
SCHEMBL8556024 0.78 RAB9A (0.44) RAB9ASMN1; SMN2NPC1POLBTDP1
SCHEMBL7692487 0.77 RAB9A (0.64) RAB9ASMN1; SMN2NPC1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020007071-A1 Benzimidzolyl neuropeptide Y receptor antagonists BRITTON THOMAS CHARLES (US) 2002-01-17 US disclosed
US-6255494-B1 SUBSTITUTED BENZIMIDAZOLES USEFUL IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH EXCESS OF NEUROPEPTIDE Y (AROUND ARTERIES IN HEART, RESPIRATORY TRACT, GASTROINTESTINAL TRACT AND GENITOURINARY TRACT); ETIOLOGY OF PSYCHIATRIC DISORDERS ELI LILLY AND COMPANY 2001-07-03 US disclosed
EP-0871442-A1 BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1998-10-21 EP disclosed
WO-1997025041-A1 BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020007071-A1 Benzimidzolyl neuropeptide Y receptor antagonists NPY1R, NPY2R, NPY5R RAB9A 3072/4885SMN1; SMN2 2698/4885NPC1 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.